ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last4,501 to 4,520 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
MiStent® vs XIENCE EES: POCE93 of 703

101 of 695

-1.3 points

-4.9 to 2.3

1,398NCT02385279

Study Comparing the MiStent SES Versus the XIENCE EES Stent

MiStent® vs XIENCE EES: Stent Thrombosis5 of 703

6 of 695

-0.2 points

-1.2 to 0.9

1,398NCT02385279

Study Comparing the MiStent SES Versus the XIENCE EES Stent

MiStent® vs XIENCE EES: Number of Participants With Occurrence of a Device Oriented Composite Endpoint (DOCE)40 of 703

45 of 695

-0.8 points

-3.3 to 1.7

1,398NCT02385279

Study Comparing the MiStent SES Versus the XIENCE EES Stent

MiStent® vs XIENCE EES: Any Revascularization61 of 703

78 of 695

-2.5 points

-5.7 to 0.6

1,398NCT02385279

Study Comparing the MiStent SES Versus the XIENCE EES Stent

MiStent® vs XIENCE EES: Target Vessel Failure (TVF)45 of 703

53 of 695

-1.2 points

-3.9 to 1.5

1,398NCT02385279

Study Comparing the MiStent SES Versus the XIENCE EES Stent

MiStent® vs XIENCE EES: deaths from any cause85 of 703

78 of 695

0.9 points

-2.5 to 4.2

1,398NCT02385279

Study Comparing the MiStent SES Versus the XIENCE EES Stent

MiStent® vs XIENCE EES: MACE65 of 703

65 of 695

-0.1 points

-3.2 to 3.0

1,398NCT02385279

Study Comparing the MiStent SES Versus the XIENCE EES Stent

MiStent® vs XIENCE EES: serious adverse events434 of 703

426 of 695

0.4 points

-4.6 to 5.5

1,398NCT02385279

Study Comparing the MiStent SES Versus the XIENCE EES Stent

Azithromycin (n=702) vs Placebo (n=696): deaths from any cause15 of 702

19 of 696

-0.6 points

-2.3 to 1.1

1,398NCT02414399

Azithromycin to Prevent Post-discharge Morbidity and Mortality in Kenyan Children

Azithromycin (n=702) vs Placebo (n=696): serious adverse events52 of 702

54 of 696

-0.4 points

-3.2 to 2.5

1,398NCT02414399

Azithromycin to Prevent Post-discharge Morbidity and Mortality in Kenyan Children

Pembrolizumab/Vibostolimab vs Pembrolizumab: serious adverse events109 of 698

57 of 700

7.5 points

4.1 to 10.9

1,398NCT05665595

A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)

Egg-derived Vaccine (TIV) vs Cell Culture-derived Vaccine (cTIV): serious adverse events10 of 396

20 of 1,001

0.5 points

-1.0 to 2.7

1,397NCT00560066

Safety of a Influenza Vaccine Produced Either in Mammalian Cell Culture or in Embryonated Hen Eggs in Adults and Elderly With and Without Underlying Medical Conditions, and Immunogenicity in a Subset of Subjects With Underlying Medical Conditions

GFRS EPD vs GEF EPD: serious adverse events18 of 425

36 of 972

0.5 points

-1.5 to 3.1

1,397NCT01343667

GORE Flow Reversal System and GORE Embolic Filter Extension Study

C31G vs Conceptrol: serious adverse events10 of 836

12 of 560

-0.9 points

-2.6 to 0.4

1,396NCT00274261

Study of the Safety and Contraceptive Efficacy of C31G Compared to Conceptrol®

Active Treatment Phase: Laquinimod 0.6 mg vs Active Treatment Phase: Laquinimod 1.2 mg: Active Treatment Phase: Number of Participants With Potentially Clinically Significant Abnormal Serum Chemistry887 of 891

501 of 504

0.1 points

-0.7 to 1.3

1,395NCT01707992

The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)

Active Treatment Phase: Laquinimod 0.6 mg vs Active Treatment Phase: Laquinimod 1.2 mg: Active Treatment Phase: Number of Participants With Potentially Clinically Significant Abnormal Hematology Values886 of 891

499 of 504

0.4 points

-0.5 to 1.8

1,395NCT01707992

The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)

Active Treatment Phase: Laquinimod 0.6 mg vs Active Treatment Phase: Laquinimod 1.2 mg: Active-Treatment Phase: Number of Participants With AEs442 of 891

241 of 504

1.8 points

-3.7 to 7.2

1,395NCT01707992

The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)

Active Treatment Phase: Laquinimod 0.6 mg vs Active Treatment Phase: Laquinimod 1.2 mg: Active-Treatment Phase: Number of Participants With Clinically Significant Vital Signs Abnormalities17 of 891

7 of 504

0.5 points

-1.1 to 1.9

1,395NCT01707992

The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)

Enzalutamide 160 mg vs Placebo: Number of Participants With Treatment-Emergent Adverse Events Greater Than or Equal to Grade 3, Based on National Cancer Institute (NCI) Common Terminology Criteria (CTC) for AEs (CTCAE), Version 4.0292 of 930

109 of 465

8.0 points

3.0 to 12.7

1,395NCT02003924

Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer

Enzalutamide 160 mg vs Placebo: Number of Participants With Discontinuations From Study Treatment Due to Adverse Events (AEs)87 of 930

28 of 465

3.3 points

0.3 to 6.1

1,395NCT02003924

Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=226"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=226

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT02385279-7790b5b8",
        "title": "MiStent® vs XIENCE EES: POCE",
        "summary": "93 of 703 against 101 of 695; risk difference -1.3 points, 95% interval -4.9 to 2.3; NCT02385279, Study Comparing the MiStent SES Versus the XIENCE EES Stent",
        "record": "/library/comparisons/NCT02385279-7790b5b8",
        "nct_id": "NCT02385279",
        "kind": "outcome",
        "participants": 1398,
        "risk_difference": {
          "value": -0.013033556085430387,
          "lower": -0.04942305757177576,
          "upper": 0.02330034650600197
        },
        "group_1": "93 of 703",
        "group_2": "101 of 695",
        "difference": "-1.3 points",
        "interval": "-4.9 to 2.3",
        "trial_title": "Study Comparing the MiStent SES Versus the XIENCE EES Stent"
      },
      {
        "id": "NCT02385279-8863de09",
        "title": "MiStent® vs XIENCE EES: Stent Thrombosis",
        "summary": "5 of 703 against 6 of 695; risk difference -0.2 points, 95% interval -1.2 to 0.9; NCT02385279, Study Comparing the MiStent SES Versus the XIENCE EES Stent",
        "record": "/library/comparisons/NCT02385279-8863de09",
        "nct_id": "NCT02385279",
        "kind": "outcome",
        "participants": 1398,
        "risk_difference": {
          "value": -0.0015207179917516907,
          "lower": -0.012384792276822246,
          "upper": 0.009000833239810017
        },
        "group_1": "5 of 703",
        "group_2": "6 of 695",
        "difference": "-0.2 points",
        "interval": "-1.2 to 0.9",
        "trial_title": "Study Comparing the MiStent SES Versus the XIENCE EES Stent"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=227",
  "request_id": "l2zZOs11PEl7bD0W"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

Instruments

The conductscience.com catalog

One instrument from the ConductScience store with the tests, measures and species it is used for, the papers that used it, and the MeSH topics of those papers.

Drugs and targets

Open Targets

One drug with its targets, the diseases it is studied for, and the trials that name it, with their comparisons, papers and cognitive tests.

Diseases

Open Targets

One disease with the drugs studied for it, the targets those drugs act on, and the trials that study it, with their comparisons and papers.

Companies

ClinicalTrials.gov

One company with the trials it leads or helps run, the drugs those trials test, the conditions they study and the organizations it runs them with.

Cell lines

Cellosaurus

One cell line with the problems Cellosaurus records for it, its relatives, the cell banks that hold it, and the papers that used it.

Journal index

PubMed and NLM's journal list

One journal with its papers in PubMed since 1959, year by year, its retracted papers, errata and expressions of concern, and how many of its papers have a copy in PMC.

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?